Efficient Screening and Design of Variable Domain of Heavy Chain Antibody Ligands Through High Throughput Sequencing for Affinity Chromatography to Purify Fab Fragments.

Efficient Screening and Design of Variable Domain of Heavy Chain Antibody Ligands Through High Throughput Sequencing for Affinity Chromatography to Purify Fab Fragments. Monoclon Antib Immunodiagn Immunother. 2019 Aug 14;: Authors: Rafique A, Satake K, Kishimoto S, Hasan Khan K, Kato DI, Ito Y Abstract To design an affinity ligand for purification of antigen-binding fragment (Fab) antibody, variable domain of heavy chain antibody (VHH) phage libraries were constructed from Fab-immunized Alpaca and subjected to biopanning against Fabs. To find the specific binders, we directly applied high-throughput sequencing (HTS) analysis of the VHH sequences in the panned phages on next-generation sequencer. The efficiently enriched sequences were aligned for construction of the phylogenetic tree to be categorized into five groups. VHHs from three major groups were first selected to analyze their properties as an affinity ligand. However, those VHHs were not suitable as an affinity ligand because of lack of resistance against alkaline pH and/or difficulty in acidic elution from the affinity column. So, we further searched the candidates from minor group sequences. Among five, one VHH showed the binding ability but with low affinity against Fabs. Therefore, we improved its affinity-by-affinity maturation through error-prone PCR library techniques. The final designed VHH showed highly alkaline pH resistance and easy acidic elution together with high affinity to Fabs. Th...
Source: Monoclonal Antibodies in Immunodiagnosis and Immunotherapy - Category: Microbiology Tags: Monoclon Antib Immunodiagn Immunother Source Type: research

Related Links:

Conclusion: This review is focused not only on the mechanism by which the immune system protects us but also on the ways in which it can inflict the body and how to modulate it with therapy. Thus, understanding the interaction of a tumor with the immune system provides insights into mechanisms that can be utilized to elicit anti-tumor immune responses. Here, we have recapitulated the function of the tumor microenvironment and immune checkpoints.
Source: Current Cancer Therapy Reviews - Category: Cancer & Oncology Source Type: research
Abstract BACKGROUND: Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with programmed cell death protein 1 (PD-1) inhibitors has been associated with risk of developing immune-mediated adverse reactions (IMARs). OBJECTIVES: This review provides nurses with an overview of the safety of PD-1 inhibitors approved by the U.S. Food and Drug Administration for recurrent or metastatic SCCHN following platinum chemotherapy, as well as recommendations for assisting with the diagnosis and management of IMARs. METHODS: PubMed® searches were conducted to iden...
Source: Clinical Journal of Oncology Nursing - Category: Nursing Authors: Tags: Clin J Oncol Nurs Source Type: research
In this study, we designed a simple strategy to achieve the co-delivery of a DNA vaccine and hydrophobic immune adjuvant (R848) and to enhance the adjuvanticity of R848 via the synergistic effect of GO and R848. Thiolated low-molecular-weight polyethylenimine (TPEI1.8) was crosslinked with 4-aminothiophenol-modified GO (TGO) via the formation of disulfide bonds. Thus, TGO with its assembled TPEI1.8 could not only load R848 but also electrostatically interact with the DNA vaccine. Owing to the reducibility of the disulfide bond in the cellular environment, the DNA vaccine could be readily released. This system can significa...
Source: Journal of Industrial and Engineering Chemistry - Category: Chemistry Source Type: research
Immunotherapy drugs have so far produced underwhelming results in prostate cancer. Now a team of researchers may have figured out why and how to make these drugs work for prostate cancer patients.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Source Type: news
https://www.journalofclinicalpathways.com/news/astro-congress-urge-cms-adjust-radiation-oncology-apm Final decision expected soon. We are all waiting with bated breath. Have to say I agree with ASTRO on this one - most programs need at least one year (1/2021) to implement appropriate infrastructure to meet mandates of RO APM. Then again, Azar does need to make some cuts ASAP to account for all the immunotherapy/CAR-T products in the pipeline for 2020 . . .
Source: Student Doctor Network - Category: Universities & Medical Training Authors: Tags: Radiation Oncology Source Type: forums
Publication date: November 2019Source: European Urology Supplements, Volume 18, Issue 11Author(s): T. Butters, B. Szabados, M. Grant, W-K. Liu, J. Lam, T. Powles
Source: European Urology Supplements - Category: Urology & Nephrology Source Type: research
AbstractGall bladder carcinoma (GBC) is a worldwide problem, with a higher incidence in areas of the world where cholelithiasis is common. As GBC is usually diagnosed in an advanced stage, the mortality is high. An understanding of the molecular pathways of carcinogenesis and the mutations involved in the development and progression of GBC could be useful in early diagnosis. Understanding molecular markers of prognosis as well as predictors of outcome could also potentially benefit patients undergoing treatment. New therapies targeting major molecular pathways and immunotherapy are exciting novel therapeutic options. This ...
Source: Indian Journal of Surgical Oncology - Category: Cancer & Oncology Source Type: research
Date: Friday, 12 06, 2019; Speaker: Greg M Delgoffe, Associate Professor, Department of Immunology , University of Pittsburgh; Building: Building 10 (Clinical Center); Lipsett Amphitheater
Source: NIH Calendar of Events - Category: American Health Source Type: events
This study identifies mechanisms mediating responses to immune checkpoint inhibitors using mouse models of triple-negative breast cancer. By creating new mammary tumor models, we find that tumor mutation burden and specific immune cells are associated with response. Further, we developed a rich resource of single-cell RNA-seq and bulk mRNA-seq data of immunotherapy-treated and non-treated tumors from sensitive and resistant murine models. Using this, we uncover that immune checkpoint therapy induces T follicular helper cell activation of B cells to facilitate the anti-tumor response in these models. We also show that B cel...
Source: Cell - Category: Cytology Source Type: research
Publication date: 14 November 2019Source: Cell, Volume 179, Issue 5Author(s): Vincenzo BrontePrimary or secondary resistance to immune checkpoint therapy is often analyzed in primary tumors rather than metastases. In this issue of Cell, Jiao et al. show that the site of metastatic diffusion matters and bones empower a particularly hostile environment.
Source: Cell - Category: Cytology Source Type: research
More News: Databases & Libraries | Immunotherapy | Microbiology